Hormone Therapy Osteoporosis Approval Hurdle Unchanged By WHI, FDA Says
Executive Summary
Hormone therapy drug sponsors seeking approval for osteoporosis do not need to submit to FDA any extraordinary safety data in light of the WHI findings, Metabolic & Endocrine Division Director David Orloff, MD, said Oct. 7